Johnson & Johnson Revenue & Financials

J&J's financial profile in its post-Kenvue form reflects the premium economics of a pharmaceutical and medical device enterprise operating at scale, with gross margin characteristics more typical of a specialty pharma company than a traditional diversified healthcare conglomerate. In fiscal year 2024, J&J reported total net sales of approximately $88.821 billion — growth of approximately 4.3 percent in reported terms from fiscal 2023's $85.159 billion, with operational sales growth (excluding foreign exchange impacts) running approximately 6 to 7 percent. The Innovative Medicine segment grew to approximately $56.5 billion, driven by Darzalex's continued volume and geographic expansion, Tremfya growth, and Spravato acceleration, partially offset by early Stelara international erosion. MedTech grew to approximately $32.3 billion, driven by Biosense Webster EP catheter growth, Abiomed Impella expansion, and strong orthopaedics market share gains in the United States, partially offset by China VBP headwinds. Gross margin runs approximately 68 to 69 percent of net sales in the combined business — reflecting the patent-protected pricing of specialty pharmaceutical drugs and the premium pricing of differentiated medical devices. This gross margin profile is substantially above J&J's historical diversified rate (which was lower when the lower-margin consumer health segment contributed to the mix), and positions the company's earnings sensitivity to revenue growth favorably: each incremental dollar of Innovative Medicine pharmaceutical sales generates approximately $0.68 to $0.72 in gross profit at current margins. R&D investment of approximately $15.1 billion (approximately 17 percent of net sales) represents J&J's largest single expense category, reflecting the company's commitment to pipeline generation as its primary competitive reinvestment priority. GAAP net earnings in fiscal 2024 were affected by multiple significant non-recurring charges, including reserves related to the talc litigation settlement and other legal matters, which resulted in GAAP EPS of approximately $5.53. Adjusted (non-GAAP) net earnings, which exclude intangible asset amortization, restructuring charges, and identified legal and acquisition-related items, produced adjusted diluted EPS of approximately $9.98 — J&J's primary earnings metric for investor communication. The spread between GAAP and adjusted EPS reflects the reality that J&J is simultaneously managing an acquisition-intensive growth strategy (which creates significant acquisition-related amortization) and a major legal resolution (talc), both of which create accounting charges unrelated to the underlying operating cash generation of the business. Free cash flow of approximately $17 to $18 billion annually provides exceptional capital allocation flexibility. J&J distributed approximately $11.8 billion in dividends in fiscal 2024 (reflecting the $4.96 per share annual dividend representing the 62nd consecutive annual increase), completed the $13.1 billion Shockwave Medical acquisition, and returned additional capital through share repurchases. The AAA-rated balance sheet, with approximately $25 billion in cash and marketable securities and investment-grade long-term debt, provides acquisition capacity that enables J&J to execute multi-billion transactions while maintaining financial discipline. Return on invested capital consistently runs in the 18 to 25 percent range across the combined business, reflecting the premium economics of both pharmaceutical patent-protected revenue and device platform-anchored MedTech revenues.